News | April 25, 2024
Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Open a printable version of this pageEmail the URL of this page to a friend
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
Subscribe To Our Newsletter & Stay Updated
